Shiva has a unique 12+ years of biopharma experience in Oncology drug development, portfolio strategy and analytics, project/alliance management, operations and business development. Her expertise spans cutting-edge areas such as immuno-oncology, cell and gene therapy, immune engagers, and antibody-drug conjugates.

She currently serves as the Head of Corporate Strategy & Partnerships at Marengo Therapeutics, a Cambridge based clinical stage biotech company focused on precision immunology. In this role, she leads corporate & portfolio strategy, competitive intelligence and partnering, driving the company’s growth and strategic direction.

Before joining Marengo, she held key leadership roles at AstraZeneca spearheading Early Oncology R&D portfolio strategy and establishing the Partner of Choice initiative, a network alliance with top global academic centers. She played a pivotal role in shaping AstraZeneca’s investments in cell therapy, immune engagers, and antibody-drug conjugate portfolios, contributing significantly to the company’s innovative pipeline. Shiva’s career began in biotech, with roles at NantKwest and STC Biologics, where she gained broad experience in corporate operations, strategy, business development, and project and alliance management.

Shiva completed her undergraduate and graduate studies at Boston University with a Bachelor’s degree in Biochemistry and Molecular Biology and Master’s degree in Biotechnology. She completed her PhD research at New York University Sackler Program in Oncology and Pharmacology and received her MBA from Babson College. Her professional accomplishments have been recognized with multiple awards, including rising leadership awards and CEO honors.